HL187

HL187 is a novel monoclonal antibody developed by HanAll Biopharma for the treatment of cancer. It specifically targets TIGIT (T cell immunoreceptor with Ig and ITIM domains), an immune checkpoint receptor expressed on T cells and natural killer (NK) cells. By inhibiting TIGIT, HL187 is designed to enhance anti-tumor immune responses by reinforcing the effector function of antibodies and activating immune cells to fight cancer. The drug is part of HanAll's immuno-oncology pipeline, aiming to provide next-generation therapies that address unmet needs in current immune checkpoint inhibitor treatments[4][5][6][7]. As of 2024, HL187 remains in preclinical development[1][5].